Giant Biogene Holding Co., Ltd. (2367.HK) Comparison with companies in other sectors?

Giant Biogene Holding Co., Ltd. has a share price of 1.06B. You can analyze Giant Biogene Holding Co., Ltd. (2367.HK) competitors across different market sectors through stock heatmaps.

What are 2367.HK's NET and operating margins?

Giant Biogene Holding Co., Ltd. (2367.HK) operating margin is around 0.42, and net profit margin is approximately 0.37 as of the latest reports.

In what way does 2367.HK's earnings per share (EPS) trend reflect its financial momentum?

Giant Biogene Holding Co., Ltd. (2367.HK) EPS is 2.25 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Giant Biogene Holding Co., Ltd. is 24.69, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Giant Biogene Holding Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Giant Biogene Holding Co., Ltd. like P/E which is 24.76, P/B which is 7.18, and PEG which is 1.56. Compare them with sector averages to evaluate if the stock is priced fairly.

Giant Biogene Holding Co., Ltd.

2367.HK•HKSE

Consumer Defensive

Household & Personal Products

HK$55.55

HK$-0.45(-0.80%)

Giant Biogene Holding Co., Ltd. (2367.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$2.25

P/E Ratio

24.69

ROE

0.32%

Net Margin

0.37%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$58.81B

Shares OutstandingTotal number of shares issued

$1.06B

Book Value/ShareNet worth per share

$7.11

Revenue/ShareAnnual revenue per share

$5.53

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$2.25

Net MarginNet income as percentage of revenue

37.23%

Operating MarginOperating income as percentage of revenue

41.68%

ROEReturn on shareholders' equity

31.54%

ROAReturn on total assets

25.66%

ROCEReturn on capital employed

32.06%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.76

Cash/ShareCash and equivalents per share

$5.85

FCF YieldFree cash flow as percentage of market cap

1.40%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.66

Dividend YieldAnnual dividend as percentage of stock price

1.29%

Financial Ratios Analysis data is not available for 2367.HKFinancial Ratios Analysis details for 2367.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2367.HKSector Benchmarking details for 2367.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Giant Biogene Holding Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Giant Biogene Holding Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Giant Biogene Holding Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Giant Biogene Holding Co., Ltd.

For Giant Biogene Holding Co., Ltd., essential financial indicators include EPS 2.25, PE 24.69, and ROE 0.32. These key ratios reveal insights into Giant Biogene Holding Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Giant Biogene Holding Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Giant Biogene Holding Co., Ltd.

Metrics like Net Margin 37.23% and ROA 25.66% shed light on how well Giant Biogene Holding Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Giant Biogene Holding Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Giant Biogene Holding Co., Ltd.

Using ratios such as P/B Ratio 7.18 and PEG Ratio 1.56, investors can assess whether Giant Biogene Holding Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Giant Biogene Holding Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Giant Biogene Holding Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.001 and Cash Flow $0.76, provide a snapshot of Giant Biogene Holding Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Giant Biogene Holding Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Giant Biogene Holding Co., Ltd.

Investing in Giant Biogene Holding Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Giant Biogene Holding Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;